US › Healthcare

Intelligent Bio Solutions Inc. (INBS)

US · Healthcare · Medical Devices

$2.00+1.52%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$1.1M

Revenue YoY

+35.8%

Net profit

$-3.9M

EPS

$-0.90

EPS estimate

$-1.58

Net margin

-341.0%

EPS came in at -0.90 against a street estimate of -1.58 — a beat of 43.0%.

Key statistics

Market cap

$6.4M

Forward P/E

0.0

P/B

1.18

Book value

$1.90

EPS (TTM)

$-8.44

52-week high

$24.90

52-week low

$1.52

50-day MA

$2.21

200-day MA

$4.33

Beta

4.25

Analyst view

Analysts rate Intelligent Bio Solutions Inc. a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $12.00.

Shareholding

Insiders

2.99%

Institutions

5.99%

Largest institutional holders

Fund	Stake
Armistice Capital, LLC	4.31%
Alyeska Investment Group, L.P.	1.26%
Geode Capital Management, LLC	0.95%
Vanguard Capital Management, LLC	0.19%
Vanguard Fiduciary Trust Co	0.13%
Tower Research Capital LLC	0.04%
UBS Group AG	0.01%
Advisor Group Holdings, Inc.	0.01%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Intelligent Bio Solutions Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.